北米ナチュラルキラー（NK）細胞治療市場 – 業界動向と2030年までの予測

北米ナチュラルキラー（NK）細胞治療市場の分析と洞察

北米のナチュラルキラー（NK）細胞療法市場は、より優れた治療オプションに対するニーズの高まり、メーカーによる新製品の市場投入、需要の高まり、市場の成長につながる研究開発への投資の増加などの特徴を備えています。現在、さまざまな研究調査が行われており、メーカーが新しい革新的なNK細胞療法を開発するための競争上の優位性が生まれることが期待されており、市場の成長のためのさまざまな機会が提供されると予想されています。ただし、細胞の特異性の欠如と生体内生存率の低さ、および療法に関連する高コストにより、予測期間中の市場の成長が抑制されると予想されます。

北米のナチュラル キラー (NK) 細胞治療市場は支持的であり、病気の進行を抑えることを目指しています。Data Bridge Market Research は、北米のナチュラル キラー (NK) 細胞治療市場は 2023 年から 2030 年の予測期間中に 42.6% の CAGR で成長すると分析しています。

北米ナチュラルキラー (NK) 細胞治療薬市場レポートでは、市場シェア、新開発、製品パイプライン分析、国内および現地の市場プレーヤーの影響の詳細を提供し、新たな収益源、市場規制の変更、製品承認、戦略的決定、製品発売、地理的拡大、市場における技術革新の観点からの機会を分析します。分析と市場シナリオを理解するには、アナリスト概要についてお問い合わせください。当社のチームが、収益に影響を与えるソリューションを作成し、希望する目標を達成できるようお手伝いします。

Market Definition

Natural killer (NK) cells are large granular lymphocytes that have the ability to quickly respond to a pathological challenge. They are important components of the innate immune system and play an important role in generating an immune response against malignancies and infectious diseases caused by viral pathogens. They have been recognized to induce the direct killing of targeted cells involving cancer cells. They have the ability to recognize the multitude of infected cells without being dependent on a single antigen-expressing cell.

NK cells secrete cytokines and chemokines that recruit other immune cells such as T cells and B cells, which enhances the immune response against the tumor cells. As NK cells do not express T cell receptors, they induce a low risk of graft-versus-host disease. Moreover, iPSC cell lines derived NK cell therapy that is CAR-NK therapy overcomes the need for a long and complex manufacturing process that allows patients with aggressive tumors to afford tumor treatment as soon as possible. Along with this iPSC derived NK cells can be infused repeatedly, which enhances the immune response with dose regulation.

North America Natural Killer (NK) Cell Therapeutics Market Dynamics

This section deals with understanding the market drivers, advantages, opportunities, restraints, and challenges. All of this is discussed in detail below:

DRIVERS

• Increase in Patient Population with Chronic Diseases

Chronic diseases are diseases that generally occur in older adults that can be controlled but not cured such as heart disease, arthritis, diabetes, stroke, or cancer. They are a worldwide healthcare problem concern. The change in lifestyle along with physical inactivity, unhealthy diet, and tobacco use is increasing the burden of chronic diseases all over the world.

An increasing number of patients population with chronic diseases led the scientist and researchers to work on a new innovative therapeutic approach so as to provide patients with the best curative treatment option, which can be achieved by using NK cell therapy that has the potential to generate a strong immune response and has the anti-tumor capability as well.

• Rise in Awareness about Immunotherapies

As cancer is a devastating disease and available treatment options may cause the reoccurrence of tumors, the need for the best therapeutic approach is increasing day by day. Immunotherapies have attracted a lot of attention in recent years for the treatment of various types of malignancies. Among the immunotherapies, CAR–T cell therapies have been studied and were used as well but have several limitations, which led to the development of NK cell therapies. As a drug based on an NK cell therapeutic approach has not been approved yet, it thus needs to raise awareness among the population.

This is why several organizations and market players are launching a campaign to enhance awareness regarding NK cell therapies.

OPPORTUNITY

•  Strategic Initiatives by Market Players

Various strategic initiatives are adopted by market players which involve expansion, acquisition, and collaboration among others. These initiatives help them to increase the company’s product portfolio leading to market expansion and hence enhancing the product demand among customers, which ultimately leads the players to earn maximum revenue.

As the demand for effective and affordable NK cell immunotherapy is increasing worldwide, these strategic initiatives are taken by top market players aimed at enhancing business operations and earning more profitability in the market.

RESTRAINT/CHALLENGE

• Lack of Specificity and Poor In Vivo Survival of the cells

Lack of specificity and poor in-vivo survival of NK cells poses a challenge in front of manufacturers dealing in the market. The lack of specificity of NK cells leads to targeting the wrong cells, which can lead to ineffective treatment. Along with this, the lack of specificity and poor in-vivo survival of NK cells also reduces the therapeutic effect of administered NK cell therapy.

Such problems decrease the credibility of therapy used in clinical trials and pose a challenge in front of manufacturers while getting approval.

Recent Developments

• In January 2022, Takeda acquired Adaptate biotherapeutics to develop novel gamma delta (γδ) T cell engager therapies targeting solid tumors. Through the acquisition, Takeda will obtain Adaptate’s antibody-based γδ T cell engager platform, including pre-clinical candidate and discovery pipeline programs. Adaptate’s γδ T cell engagers are designed to specifically modulate γδ T cell-mediated immune responses at tumor sites while sparing damage to healthy cells. This acquisition helped the company to focus on R&D.
• In December 2021, Nektar Therapeutics announced phase 1b data for novel T regulatory cell stimulator NKTR-358 (LY3471851) in patients with atopic dermatitis. NKTR-358 is designed to treat autoimmune and inflammatory conditions by correcting the immune system imbalance that results from increased levels of inflammatory T cells and reduced numbers and impaired function of immune regulating Treg cells. This has helped the company to focus on R&D for further phases.

North America Natural Killer (NK) Cell Therapeutics Market Scope

The North America natural killer (NK) cell therapeutics market is segmented into five notable segments based on therapeutics, approaches, application, end-user, and distribution channel. The growth among these segments will help you analyze niche pockets of growth and strategies to approach the market and determine the core application areas and the difference in the target markets.

Therapeutics

• NK Cell Therapies
• NK Cell Directed Antibodies

Based on therapeutics, the market is segmented into NK cell therapies and NK cell directed antibodies.

Approaches

• Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC)
• Bispecific Antibodies

Based on approaches, the market is segmented into antibody-dependent cell-mediated cytotoxicity (ADCC) and bispecific antibodies.

Application

• Cancer
• Immunoproliferative Disorders
• Acute Infectious Diseases
•  Gastrointestinal Diseases
• Others

Based on application, the market is segmented into cancer, immunoproliferative disorders, acute infectious diseases, gastrointestinal diseases, and others.

End User

• Research & Academic Institutes
• Hospitals
•  Specialty Clinics

Based on end user, the market is segmented into hospitals, specialty clinics, and research & academic institutes.

Distribution Channel

• Hospital Pharmacies
•  Direct Tender
•  Others

Based on distribution channel, the market is segmented into hospital pharmacies, direct tender, and others.

North America Natural Killer (NK) Cell Therapeutics Market Regional Analysis/Insights

The North America natural killer (NK) cell therapeutics market is categorized into five notable segments: therapeutics, approaches, application, end-user, and distribution channel.

The countries covered in this market report are the U.S., Canada, and Mexico.

The U.S. is dominating the North America natural killer (NK) cell therapeutics market and is expected to grow due to the rise in technological advancement in the market.

The country section of the report also provides individual market-impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, the presence and availability of North America brands and their challenges faced due to large or scarce competition from local and domestic brands, and the impact of sales channels are considered while providing forecast analysis of the country data.

Competitive Landscape and North America Natural Killer (NK) Cell Therapeutics Market Share Analysis

北米ナチュラルキラー（NK）細胞療法市場の競争状況は、競合他社の詳細を提供します。詳細には、会社概要、会社の財務状況、収益、市場の可能性、研究開発への投資、新しい市場への取り組み、北米でのプレゼンス、生産拠点と施設、生産能力、会社の強みと弱み、製品の発売、製品の幅と広さ、アプリケーションの優位性が含まれます。上記のデータポイントは、市場に関連する会社の焦点にのみ関連しています。

北米のナチュラルキラー（NK）細胞治療薬市場で活動している主要企業には、Merck KGaA、Bristol-Myers Squibb Company、Glycostem、Sanofi、Cytovia Therapeutics、ImmunityBio, Inc.、Biohaven Pharmaceuticals、Fate Therapeutics、EMERcell、Phio Pharmaceuticals、PersonGen BioTherapeutics、Innate Pharma, Inc.、INmuneBIO、Gamida Cell、Acepodia Inc.、Affimed GmbH、Multimmune GmbH、iCell Gene Therapeutics、Takeda Pharmaceutical Company Limited、Regeneron Pharmaceuticals Inc. などがあります。

SKU-56948